DWP17061 / Daewoong Pharma - LARVOL DELTA

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients. (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: iN Therapeutics Co., Ltd. | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Feb 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • Immunology • Neuralgia • Osteoarthritis • Pain • Rheumatology

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients. (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: iN Therapeutics Co., Ltd.

New P1 trial • Immunology • Neuralgia • Osteoarthritis • Pain • Rheumatology

A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: iN Therapeutics Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Aug 2022 ➔ Oct 2023 | Trial primary completion date: Aug 2022 ➔ Oct 2023

Trial completion • Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 after Oral Administration in Healthy Volunteers (ANZCTR) - P1 | N=32 | Recruiting | Sponsor: iN Therapeutics Co., Ltd. | Initiation date: Aug 2000 ➔ Aug 2022

Trial initiation date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: iN Therapeutics Co., Ltd.

New P1 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Joint research on'Ion channel structure such as Nav1.7' with IN and POSTECH [Google translation] (Biospectator) - "​Lenterapeutics announced on the 18th that it has signed an'ion channel structure joint research agreement' with POSTECH's KIURI research team for biomolecular capture technology....The first task that the two institutions cooperate with is DWP17061, a Nav1.7 inhibitory pain treatment drug, which is currently undergoing Phase 1 clinical trials in Australia, and about 80% of the research cost is borne by the government....'We will develop innovative new drugs in various areas such as pain, hearing loss, and central nervous system diseases.'"

Licensing / partnership • CNS Disorders • Neuralgia • Pain

Lenterapeutics, clinical trial in Australia… Obtained approval for phase 1 non-narcotic pain reliever [Google translation] (The Korea Economic Daily) - "Daewoong Pharmaceutical's subsidiary Ienterapeutics announced on the 15th that it has been approved by the Australian Food and Drug Administration (TGA) for a phase 1 clinical trial of the non-narcotic pain reliever 'DWP17061'....Lenterapeutics plans to expand the indications to postoperative pain by changing the formulation of DWP17061."

New P1 trial • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Daewoong sets up iN Therapeutics to jump on spinoff bandwagon (Korea Biomedical Review) - "Daewoong Pharmaceutical has joined the ongoing 'spinoff boom' among Korean drugmakers by setting up a new drug development firm, iN Therapeutics, to secure flexibility in R&D of its promising pipelines and quickly see its results....iN Therapeutics plans to start administering DWP17061 on healthy people within this year and conduct safety and pharmacokinetics until the first half of 2021....iN Therapeutics looks to complete series A investment into its clinical development of first-in-class non-opioid pain drug...second half of 2020 and make an initial public offering in 2025."

Financing • Trial status • CNS Disorders • Neuralgia • Pain

Daewoong Pharmaceutical Diversifies the Path for New Drug Development of 'JV·Spinoff' [Google translation] (thebell) - "Daewoong Pharmaceutical plans to apply for the Australian Phase 1 Clinical Trial Plan (IND) to prove the safety, tolerability, and efficacy of DWP17061 in humans within the third quarter."

New P1 trial • CNS Disorders • Neuralgia • Pain

Daewoong Pharmaceutical to develop ion channel platform… Established Ienterapeutics [Google translation] (CEO Score Daily) - "Daewoong Pharmaceutical...established a corporation to grow the Ion Channel (VITVO) platform as one of the growth engines. Through this, it is expected to accelerate the development of high-demand chronic pain treatment....Daewoong Pharmaceutical plans to conduct a global phase 1 clinical trial of DWP17061 within this year."

New P1 trial • CNS Disorders • Neuralgia • Pain